Vaxcyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	60.7	39.81	25.26	16.02	8.55	Upgrade
Research & Development	332.34	169.45	78.41	73.56	45.61	Upgrade
Other Operating Expenses	75	23	0	0	0	Upgrade
Operating Expenses	468.04	232.26	103.67	89.58	54.15	Upgrade
Operating Income	-468.04	-232.26	-103.67	-89.58	-54.15	Upgrade
Interest Expense / Income	0	0	0.01	0.01	0.04	Upgrade
Other Expense / Income	-65.78	-8.77	-3.6	-0.37	-3.92	Upgrade
Pretax Income	-402.27	-223.49	-100.08	-89.22	-50.27	Upgrade
Net Income	-402.27	-223.49	-100.08	-89.22	-50.27	Upgrade
Shares Outstanding (Basic)	97	65	52	30	4	Upgrade
Shares Outstanding (Diluted)	97	65	52	30	4	Upgrade
Shares Change	49.75%	24.95%	75.73%	678.53%	4.55%	Upgrade
EPS (Basic)	-4.14	-3.44	-1.93	-3.02	-13.25	Upgrade
EPS (Diluted)	-4.14	-3.44	-1.93	-3.02	-13.25	Upgrade
Free Cash Flow	-364.67	-176.44	-127.92	-47.73	-48.34	Upgrade
Free Cash Flow Per Share	-3.75	-2.72	-2.46	-1.62	-12.74	Upgrade
EBITDA	-392.1	-214.29	-96.61	-87.81	-49	Upgrade
Depreciation & Amortization	10.17	9.2	3.46	1.41	1.23	Upgrade
EBIT	-402.27	-223.48	-100.07	-89.21	-50.23	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).